CBCRisk model to determine the risk of contralateral breast cancer in sporadic breast cancer

被引:0
作者
Breton, Maria Domingo [1 ]
Cabanuz, Marta Allue [1 ]
Villanueva, Nestor Castan [1 ]
Arribas Del Amo, Maria Dolores [2 ]
Romea, Ismael Gil [2 ]
Sanchez, Antonio Guemes [2 ]
机构
[1] Hosp Clin Univ Lozano Blesa, Serv Cirugia Gen, Zaragoza, Spain
[2] Hosp Clin Univ Lozano Blesa, Serv Cirugia Gen, Unidad Mama, Zaragoza, Spain
来源
CIRUGIA ESPANOLA | 2021年 / 99卷 / 10期
关键词
Breast cancer; Risk-reducing mastectomy; Contralateral prophylactic mastectomy; Risk assessment; CBCRisk; PROPHYLACTIC MASTECTOMY; CONSENSUS-STATEMENT; OUTCOMES; TREND;
D O I
10.1016/j.ciresp.2020.11.007
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: The great majority of breast cancer (BC) cases are diagnosed in women who have no known family history of the disease and are not carriers of any risk mutation. During the past few decades an increase in the number of contralateral prophylactic mastectomy (CPM) has been produced in these patients. The CBCRisk model calculates the absolute risk of suffering from contralateral breast cancer (CBC); thus, it can be used to counselling patients with sporadic breast cancer. Method: An observational, retrospective study including sporadic breast cancer patients treated with contralateral prophylactic mastectomy has been conducted between 2017 and 2019. A descriptive and comparative study with one variation of logistic regression has been carried out in order to identify predictive factors of occult tumors (OT) and medium/high risk damage (MHRD). Evaluation of the CBCRisk model published in 2017 and different limit values for the CPM recommendation. Results: 42 patients were selected. Incidence of MHRD and OT was lower than that described in the literatura (9.52%MHRD, 2.38%OT). None of the evaluated variables reached statistical significance for predicting injuries. The average value of CBCRisk 5 years ahead found in patients with pathological findings was 2.08 (DE 0.97), higher than the average value of the whole group (1.87 +/- 0.91) and the subgroup without pathological findings (1.84 +/- 0.91). Only values >3 for CBCRisk were considered statistically significant (P =.04) for the prediction of histological lesions. Conclusion: Patients with sporadic breast cancer should be adequately informed about the estimated risks and benefits of undergoing a contralateral prophylactic mastectomy. The CBCRisk may be useful for the counseling of these patients, but it requires validation in larger and prospective cohorts. (C) 2020 AEC. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:724 / 729
页数:6
相关论文
共 14 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies
    Basu, N. N.
    Barr, L.
    Ross, G. L.
    Evans, D. G.
    [J]. INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY, 2015, 2015
  • [3] Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients
    Bedrosian, Isabelle
    Hu, Chung-Yuan
    Chang, George J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (06): : 401 - 409
  • [4] Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks
    Boughey, Judy C.
    Attai, Deanna J.
    Chen, Steven L.
    Cody, Hiram S.
    Dietz, Jill R.
    Feldman, Sheldon M.
    Greenberg, Caprice C.
    Kass, Rena B.
    Landercasper, Jeffrey
    Lemaine, Valerie
    MacNeill, Fiona
    Song, David H.
    Staley, Alicia C.
    Wilke, Lee G.
    Willey, Shawna C.
    Yao, Katharine A.
    Margenthaler, Julie A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (10) : 3100 - 3105
  • [5] Validation of a personalized risk prediction model for contralateral breast cancer
    Chowdhury, Marzana
    Euhus, David
    Arun, Banu
    Umbricht, Chris
    Biswas, Swati
    Choudhary, Pankaj
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 415 - 423
  • [6] A model for individualized risk prediction of contralateral breast cancer
    Chowdhury, Marzana
    Euhus, David
    Onega, Tracy
    Biswas, Swati
    Choudhary, Pankaj K.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (01) : 153 - 160
  • [7] Contralateral Prophylactic Mastectomy: Long-Term Consistency of Satisfaction and Adverse Effects and the Significance of Informed Decision-Making, Quality of Life, and Personality Traits
    Frost, Marlene H.
    Hoskin, Tanya L.
    Hartmann, Lynn C.
    Degnim, Amy C.
    Johnson, Joanne L.
    Boughey, Judy C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (11) : 3110 - 3116
  • [8] Increasing rates of contralateral prophylactic mastectomy - A trend made in USA?
    Gueth, U.
    Myrick, M. E.
    Viehl, C. T.
    Weber, W. P.
    Lardi, A. M.
    Schmid, S. M.
    [J]. EJSO, 2012, 38 (04): : 296 - 301
  • [9] Occult Malignancy in Patients Undergoing Contralateral Prophylactic Mastectomy
    King, Tari A.
    Gurevich, Inga
    Sakr, Rita
    Patil, Sujata
    Stempel, Michelle
    Morrow, Monica
    [J]. ANNALS OF SURGERY, 2011, 254 (01) : 2 - 7
  • [10] Post-mastectomy pain syndrome: Incidence and risks
    Nogueira Fabro, Erica Alves
    Bergmann, Anke
    do Amaral e Silva, Blenda
    Padula Ribeiro, Ana Carolina
    Abrahao, Karen de Souza
    da Costa Leite Ferreira, Maria Giseli
    Dias, Ricardo de Almeida
    Santos Thuler, Luiz Claudio
    [J]. BREAST, 2012, 21 (03) : 321 - 325